Jonathan Allan sold $92k of STOK
GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc.. 2,861 shares at an average of $32.03, traded Aug 18, 2026, filed Aug 18, 2026.
Score components
- +15RoleOfficer
- +9Trade size$92k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001966716-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | MOption exercise Common Stock | +6,000 | $0.00 | $0 | 24,086 | Aug 18, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock | -2,716 | $32.01 | $87k | 21,370 | Aug 18, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock | -145 | $32.47 | $4,708 | 21,225 | Aug 18, 2026 |
| Aug 14, 2026 | MOption exercise Performance Stock Unitsderivative | -6,000 | $0.00 | $0 | 0 | Aug 18, 2026 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 26Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 31Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $403k 12,567 shares | -9% | |
| 31Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $153k 4,767 shares | -16% | |
| 17Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $208k 7,176 shares | -26% | |
| 13Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $236k 7,228 shares | -21% | |
| 1Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $44k 1,457 shares | -7% | |
| 2Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $55k 1,795 shares | -5% | |
| 3Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $74k 2,243 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.